AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2025
Jun 30, 2025
30604_dirs_2025-06-30_f91e501c-891a-4b2f-bc7d-bcaac5ad773c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-28
Reporting Person: Valantine Hannah (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-28 | Common Stock | P | 1542 | $12.68 | Acquired | 1542 | Direct |
| 2021-12-28 | Common Stock | P | 796 | $13.16 | Acquired | 2687 | Indirect |
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3